Sergio Duarte Dortas Junior

@unifase-rj.edu.br

Hospital Universitário Clementino Fraga Filho (HUCFF-UFRJ)
Centro Universitário Arthur Sá Earp Neto/Faculdade de Medicina de Petrópolis - UNIFASE/FMP

Sergio Duarte Dortas Junior


                  Download Compact PDF  
https://researchid.co/sdortasjr

RESEARCH INTERESTS

Urticaria; Angioedema; Chronic Rhinosinusitis; Severe Asthma; Drug Hypersensitivity
21

Scopus Publications

Scopus Publications

  • Real-World Evidence on the Management of Hereditary Angioedema With Normal C1 Inhibitor
    Nyla Thyara Melo Lobão, Maine Luellah Demaret Bardou, Shirley Yajaira Cerinza Vila, Lucas Salomão de Sousa Ferreira, Luisa Karla Arruda, José Eduardo Seneda Lemos, Mariana Paes Leme Ferriani, Marina Mendonça Dias, Eliana Cristina Toledo, Faradiba Sarquis Serpa, Therezinha Ribeiro Moyses, Herberto J. Chong-Neto, Nelson Augusto Rosário Filho, Caroline Guth de Freitas Batista de Moraes, Fernanda Casares Marcelino, Eli Mansour, Caroline Rosa Emergente Coutinho, Ronney Corrêa Mendes, Rozana de Fátima Gonçalves, Solange Oliveira Rodrigues Valle, Maria Luiza Oliva-Alonso, Sérgio Duarte Dortas Junior, Jane da Silva, Aline Lara Fonseca de Souza, Luis Felipe Ensina, Vanessa Morato, Regis de Albuquerque Campos, João Bosco Pesquero, Rosemeire Navickas Constantino-Silva, Anete Sevciovic Grumach
    Journal of Allergy and Clinical Immunology in Practice, 2026
  • Family quality-of-life burden in chronic spontaneous urticaria: A multicentre study
    Beatrice Martinez Zugaib Abdalla, Roberta Fachini Jardim Criado, Kanokvalai Kulthanan, Emek Kocatürk, Ivan Cherrez‐Ojeda, Ana Maria Giménez‐Arnau, Marcus Maurer, Luis Felipe Ensina, Jonathan A. Bernstein, Michihiro Hide, Sergio Duarte Dortas Junior, Solange Oliveira Rodrigues Valle, Gabriela Dias, Paraskevi Xepapadak, Priyanshi Dangi, Indrashis Podder, Vesna Trajkova, Natasa Teovska Mitrevska, Iman Hamed Nasr, Bushra Al Hinai, Joanna Bartosińska, Dorota Krasowska, Paulina Szczepanik‐Kułak, Hilal Gungor, Deniz Ozceker, Kübra Çiçek, Esen Özkaya, Yasemin Erdem, Mücahit Ergün, Mustafa Tosun, Rabia Oztas Kara, Jie Li, Anastasia Allenova, Paulo Ricardo Criado
    Journal of the European Academy of Dermatology and Venereology, 2026
    Background Chronic spontaneous urticaria (CSU) can cause psychosocial and quality of life burden on patients and their family members and caregivers. Despite its recognition as a debilitating disease, limited data exist regarding the impact of CSU on family members, hindering a comprehensive understanding of the disease's broader effects. This study aimed to assess how CSU affects the quality of life of family members who support patients in their daily challenges by applying the Family Dermatology Life Quality Index (FDLQI) questionnaire across multiple countries. Methods A cross‐sectional, multicentre and international study conducted between January and December 2024 in Urticaria Centres of Reference and Excellence (UCARE) centres located in several countries including Brazil, China, Ecuador, Greece, India, Oman, Poland, Russia, Thailand, Turkey, Peru and North Macedonia. Statistical analyses, including non‐parametric tests and multiple regression models, were employed to explore associations between disease severity/control and family burden. Results Poorly controlled CSU significantly deteriorated family members' quality of life, particularly in emotional, physical and social domains. Higher disease severity and lower disease control scores were associated with increased stress, greater caregiving burden and elevated health expenditures. In opposition to family relations, older age and longer time since diagnosis mitigate negative impacts, while insufficient treatment regimens exacerbated them. Conclusion Inadequate control of CSU amplifies the burden on families, underscoring the need for effective and supportive care strategies.
  • Rhinosinusitis: Evidence and experience – 2024
    Fabrizio Ricci Romano, Wilma Terezinha Anselmo-Lima, Eduardo Macoto Kosugi, Eulalia Sakano, Fabiana Cardoso Pereira Valera, Marcus Lessa, Renato Roithmann, Shirley Pignatari, Alexandre Wady Debes Felippu, Camila Degen Meotti, Carolina Cincurá Barreto, Dirceu Solé, Ekaterini Simões Goudouris, Fábio Chigres Kuschnir, Fabio de Rezende Pinna, Faradiba Sarquis Serpa, Gabriela Ricci Lima Luz Matsumoto, Gustavo Subtil Magalhães Freire, João Ferreira Mello, José Laerte Boechat, Leonardo Lopes Balsalobre Filho, Marcel Menon Miyake, Marcio Nakanishi, Marco Aurélio Fornazieri, Mariana Dalbo Contrera Toro, Miguel Soares Tepedino, Norma de Paula Motta Rubini, Olavo de Godoy Mion, Ricardo Landini Lutaif Dolci, Richard Louis Voegels, Roberto Eustáquio Guimarães, Sérgio Duarte Dortas, Thiago Freire Pinto Bezerra, Vanessa Ramos Pires Dinarte, Edwin Tamashiro, Otávio Bejzman Piltcher
    Brazilian Journal of Otorhinolaryngology, 2025
    It has been 10-years since the publication of Rhinosinusitis: evidence and experience, and since then a lot has changed in our understanding of the disease. Advances in pathophysiology, endotyping and new treatments such as biologics brought a new era in the management of our patients. This new guideline, developed jointly by ABR and ABORL-CCF, with the help of ASBAI presents an updated, evidence-based approach to the different forms of rhinosinusitis that aims to improve the diagnosis and treatment of this complex disease. The document covers a wide range of topics, including clear definitions of the different stages of acute sinusitis. It also introduces a new term called Prolonged Acute Viral Rhinosinusitis. Reviews phenotypes and endotypes of chronic rhinosinusitis, recommending methods for clinical and laboratory investigation, clinical and surgical treatment. We also discuss in detail fungal sinusitis and pediatric sinusitis. The objective of this updated Consensus is to clarify some already established and recent concepts, highlighting the importance of an accurate diagnosis to promote treatment approaches that reflect the best practices based on solid evidence. Therefore, we seek not only to improve the results of patients care, but also to guide thealth professionals through a clinical panorama that is in constant transformation.
  • A real-world study in Brazilian patients with atopic dermatitis treated with dupilumab who previously received methotrexate and cyclosporine
    Cinthia Dinis da Costa, Sergio Duarte Dortas Jr, Omar Lupi
    Allergologia Et Immunopathologia, 2025
    Introduction: Atopic Dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts patients´ quality of life. Dupilumab was Brazil´s first biologic approved to treat moderate-to-severe AD. We aimed to assess the effectiveness and safety of dupilumab in a real-life setting for 16 weeks. Methods: Fourteen patients were evaluated at weeks 0, 4, and 16 after the first dupilumab shot. At each visit, disease activity and severity, itching intensity, and impact on quality of life were measured using the EASI (Eczema Area and Severity Index), IGA (Investigator’s Global Assessment), SCORAD (Scoring Atopic Dermatitis), NRS (Numeric Rating Scale for itching), and DLQI (Dermatology Life Quality Index). Results: Clinical improvement observed was significant, with variation in all scores used in the study sample during the first 16 weeks of treatment (p < 0.0001). Conclusion: Dupilumab was effective and safe in our patients with moderate-to-severe AD.
  • Development of a mobile app for the evaluation of patients with chronic rhinosinusitis
    Priscila Novaes Ferraiolo, Sergio Duarte Dortas, Fabiana Chagas da Cruz, Priscilla Campos de Souza Ramos, José Elabras Filho, Marise da Penha Costa Marques, Cláudia Maria Valete-Rosalino
    Brazilian Journal of Otorhinolaryngology, 2024
    OBJECTIVE: To develop a mobile application with a standardized routine, to be used by general otolaryngologists for evaluating patients with chronic rhinosinusitis. METHODS: A systematic review was made to identify outcomes, recommendations and what tests that would be used in the routine evaluation of patients with chronic rhinosinusitis; establish an expert consensus on items to be included in this routine evaluation of patients with chronic rhinosinusitis using the Delphi method; development of an application for use on a mobile device, with the routine evaluation of patients with chronic rhinosinusitis. RESULTS: Based on the systematic review, the outcomes used in studies about chronic rhinosinusitis were identified, as well as guidelines recommendations, which showed discrepancies between them. These recommendations and outcomes were presented to specialists in chronic rhinosinusitis, until a consensus was reached. As a result of the Delphi method, the flowchart of the routine evaluation of patients with chronic rhinosinusitis was defined, and then was used for the development of the mobile application. CONCLUSION: The creation of the mobile application for evaluating patients with chronic rhinosinusitis followed an adequate methodology of elaboration made by specialists in the field of chronic rhinosinusitis, standardizing the investigation of these patients. LEVEL OF EVIDENCE: Level 5.
  • Chronic urticaria: profile from a reference center
    Ana Carolina Miranda Carvalho Ferreira Fernandes de Souza, Sérgio D. Dortas Junior, Guilherme Gomes Azizi, Alfeu Tavares França, Omar Lupi, Solange O.R. Valle
    Anais Brasileiros De Dermatologia, 2022
  • Acquired Angioedema due to C1-Inhibitor Deficiency: A Challenging Condition
    Solange Oliveira Rodrigues Valle, Maria Luiza Oliva Alonso, Sérgio Duarte Dortas Junior, Ekaterini Simões Goudouris, Ana Luiza Ribeiro Bard de Carvalho, Albertina Varandas Capelo, Eli Mansour, Ana Flávia Bernardes, Luiz Fernando Bacarini Leite, Pedro Giavina-Bianchi, Marcelo Vivolo Aun, Mariana Paes Leme Ferriani, Luisa Karla Arruda, Anete Sevciovic Grumach
    International Archives of Allergy and Immunology, 2022
    <b><i>Background:</i></b> Acquired deficiency of C1 inhibitor (AAE-C1-INH) is a very rare cause of recurrent angioedema, with few cases reported in the literature. We aimed to describe a series of patients with AAE-C1-INH who were diagnosed and received care at angioedema reference centers in Brazil, affiliated to the Brazilian Group of Studies on Hereditary Angioedema. <b><i>Methods:</i></b> Fourteen patients from 8 Brazilian Angioedema Reference Centers, diagnosed with AAE-C1-INH, were included in this study. Clinical data collected included sex, date of birth, date of onset of symptoms, date of diagnosis, plasma levels of antigenic and/or functional C1-INH, levels of C4 and C1q, location and treatment of angioedema attacks, long-term prophylaxis, associated diseases, and definitive treatment. <b><i>Results:</i></b> Fourteen patients were identified with AAE-C1-INH. Most patients (10/14; 71.4%) were female. The median age at onset of symptoms was 56.5 years (range, 14–74 years; interquartile range [IQR], 32–64 years), and median age at diagnosis was 58.0 years (range, 20–76 years; IQR, 38–65 years), with a median time until diagnosis of 2 years (range, 0–6 years; IQR, 1–3 years). The most common manifestations were cutaneous (face, eyelids, lips, trunk, hands, feet, and genitals). Most patient had low levels of C4 (13/14; 92.8%) and of antigenic C1-INH (8/14; 57.1%). Four had decreased functional activity of C1-INH (4/7; 57.1%) and C1q levels were low in 5 patients (5/12; 41.6%). Underlying diseases were identified in all 14 patients, with lymphoma of the splenic marginal zone and monoclonal gammopathy of undetermined significance being the most frequent. Nine patients (64.2%) needed long-term prophylactic treatment for recurrent angioedema and 5 patients (46.7%) required treatment for angioedema attacks. Most of them (12/14; 85.7%) had resolution of angioedema. <b><i>Conclusion:</i></b> Therapy of AAE-C1-INH aims to control symptoms; however, diagnosis and treatment of the underlying disease, when present, should be an important target and may lead to the resolution of angioedema in patients with AAE-C1-INH.
  • COVID-19 triggers attacks in HAE patients without worsening disease outcome
    María Margarita Olivares, Ricardo Dario Zwiener, Lina Maria Leiva Panqueva, Francisco Alberto Contreras Verduzco, Eli Mansour, Jairo Antonio Rodriguez, Solange Oliveira Rodrigues Valle, Sandra Nieto-Martínez, Jane da Silva, Daniel O. Vazquez, Oscar Calderon Llosa, Fernanda Casares Marcelino, Manuel Ratti Sisa, Ileana María Madrigal Beas, Rafael Zaragoza Urdaz, Eliana Toledo, Natalia Lorena Fili, Olga M. Barrera, Juan Carlos Fernandez de Cordova Aguirre, Sergio Castro Mora, Mauricio Sarrazola, Rodolfo Jaller Raad, Edison Morales Cardenas, Dario Oscar Josviack, Claudio Fantini, Monica Marocco, Elma I. Nievas, Faradiba Sarquis Serpa, Herberto J. Chong-Neto, Maria Luiza Oliva Alonso, Sergio Dortas Junior, Raisa Gusso Ulaf, Nelson Rosário, Rodolfo Ramón Leyva Barrero, Anete Sevciovic Grumach
    Journal of Allergy and Clinical Immunology in Practice, 2022
  • Spiritual well-being and quality of life are impaired in chronic urticaria
    S.D. Dortas Junior, G.G. Azizi, R.N. Moret, R.M. Bastos Junior, S.O.R. Valle
    European Annals of Allergy and Clinical Immunology, 2021
    Background. Patients with chronic urticaria (CU) often report an impaired quality of life (QoL). Although a positive effect of addressing spirituality in health care has been proved in several chronic diseases, its potential role in CU has received no attention. Objective. We aim to evaluate spirituality and QoL in CU subjects. Methods. In a single-centre observational study, 100 CU subjects were investigated using Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being (FACIT-Sp-12) scale, Chronic Urticaria Quality of life Questionnaire (CU-Q2oL) and Urticaria Control Test (UCT). Results. Of 100 subjects, 82 were female and 18 were male. It was observed that subjects with poorly controlled CU presented FACIT Sp-12 meaning/peace (p = 0.004) significantly lower, and CU-Q2oL (p < 0.0001) significantly higher (worst QoL) than subjects with controlled CU. There was no difference in the FACIT Sp-12 faith (p = 0.43) between groups. There was moderate direct correlation between FACIT Sp-12 faith and FACIT Sp-12 meaning/peace (r = 0.483; p < 0.0001; n = 100). There was a significant strong inverse correlation between the CU-Q2oL and the UCT (r = -0.762; p < 0.0001; n = 100). No correlation was found between the FACIT Sp-12 faith and CU-Q2oL, neither with UCT. Conclusions. No study has ever investigated the role of spirituality in managing patients with urticaria. Our findings support the impact of poorly controlled urticaria in spiritual well-being and QoL. Therefore, clinicians should pay more attention to spirituality among CU patients. We suggest that urticaria guidelines should include specific recommendations on spirituality assessment.
  • The Challenges in the Follow-Up and Treatment of Brazilian Children with Hereditary Angioedema
    Joanna Araújo-Simões, Aline Gisele Pena Boanova, Rosemeire Navickas Constantino-Silva, Nyla Thyara Melo Lobão Fragnan, Jorge Andrade Pinto, Fernanda G. Minafra, Rozana Fátima Gonçalves, Solange Rodrigues do Valle, Maria Luiza Oliva Alonso, Sergio Duarte Dortas, Ekaterine Simões Goudouris, Almerinda Maria Rêgo-Silva, Mayara Madruga Marques, Faradiba S. Serpa, Herberto Jose Chong-Neto, Rosario Filho Nelson, Eli Mansour, Iramirton Figuerêdo Moreira, Adriana S. Moreno, Luisa Karla Arruda, Pérsio Roxo Junior, Mariana Paes Leme Ferriani, Jane Silva, Janaira Fernandes Severo Ferreira, Pedro Giavina-Bianchi, Priscila M. Takejima, Luis Felipe Ensina, Regis de Albuquerque Campos, Eliana Toledo, João Bosco Pesquero, Sandra Mitie Ueda Palma, Camila Lopes Veronez, Anete Sevciovic Grumach
    International Archives of Allergy and Immunology, 2021
    &lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Hereditary angioedema (HAE) with C1 inhibitor (C1-INH) deficiency is a rare autosomal dominant disease. Although the first symptoms can appear in childhood, the diagnosis’s delay has a strong impact on the patient’s quality of life. We analyzed clinical and laboratory characteristics and the drug therapy of pediatric patients with HAE in Brazil. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Medical records from 18 reference centers of HAE patients under 18 years of age were evaluated after confirmed diagnosis was performed by quantitative and/or functional C1-INH. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; A total of 95 participants (51 M:44 F; mean age: 7 years old) out of 17 centers were included; 15 asymptomatic cases were identified through family history and genetic screening. Angioedema attacks affected the extremities (73.5%), gastrointestinal tract (57%), face (50%), lips (42.5%), eyelids (23.7%), genitals (23.7%), upper airways (10%), and tongue (6.3%). Family history was present in 84% of patients, and the mean delay in the diagnosis was 3.9 years. Long-term prophylaxis (51/80) was performed with tranexamic acid (39/80) and androgens (13/80); and short-term prophylaxis (9/80) was performed with tranexamic acid (6/80) and danazol (3/80). On-demand therapy (35/80) was prescribed: icatibant in 7/35, fresh frozen plasma in 16/35, C1-INH plasma-derived in 11/35, and tranexamic acid in 12/35 patients. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; This is the first study on HAE pediatric patients in Latin America. Clinical manifestations were similar to adults. Drugs such as androgens and tranexamic acid were indicated off-label, probably due to restricted access to specific drugs. Educational programs should address pediatricians to reduce late diagnosis and tailored child therapy.
  • COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency
    Anete S. Grumach, Ekaterini Goudouris, Sergio Dortas Junior, Fernanda Casares Marcelino, Maria Luiza Oliva Alonso, Raquel de Oliveira Martins, Maria Angelica Arpon, Solange Oliveira Rodrigues Valle
    Journal of Allergy and Clinical Immunology in Practice, 2021
  • Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria
    Sérgio Dortas Junior, Guilherme Azizi, Solange Valle
    Annals of Allergy Asthma and Immunology, 2020
  • Validity, reliability, and interpretability of the Brazilian urticaria control test
    Sérgio Duarte Dortas Junior, Solange Oliveira Rodrigues Valle, Karsten Weller, Marcus Maurer, Omar Lupi
    Allergy and Asthma Proceedings, 2020
  • H1-antihistamines may no longer be necessary for patients with refractory chronic spontaneous urticaria after initiation of omalizumab
    LF Ensina, LK Arruda, RA Campos, RF Criado, S Rodrigues Valle, JML Melo, JCS Oliveira, SD Dortas Jr, AP Cusato- Ensina, IC Camelo-Nunes, RC Agondi
    Journal of Investigational Allergology and Clinical Immunology, 2020
  • Hereditary angioedema: Screening of first-degree blood relatives and earlier diagnosis
    Solange O. R. Valle, Maria Luiza O. Alonso, Rosangela P. Tortora, Augusto T. Abe, Soloni A. P. Levy, Sérgio D. Dortas
    Allergy and Asthma Proceedings, 2019
  • Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
    Fernanda Sales da Cunha, Solange Oliveira Rodrigues Valle, José Elabras Filho, Sérgio Duarte Dortas Júnior, Alfeu Tavares França
    Jornal Brasileiro De Pneumologia, 2018
  • Impact of chronic urticaria on the quality of life of patients followed up at a university hospital
    Gabriela Andrade Coelho Dias, , Gisele Viana Pires, Solange Oliveira Rodrigues do Valle, Sérgio Duarte Dortas Júnior, Soloni Levy, Alfeu Tavares França, Ilaria Baiardini, Walter Giorgio Canonica, , , and
    Anais Brasileiros De Dermatologia, 2016
  • Prevalence of autoantibodies in a group of Hereditary Angioedema patients
    Sergio Duarte Dortas Junior, Solange Oliveira Rodrigues Valle, Soloni Afra Pires Levy, Rosangela P. Tortora, Augusto Tiaqui Abe, Gisele Viana Pires, José Angelo de Souza Papi, Alfeu Tavares França
    Anais Brasileiros De Dermatologia, 2012
  • Atopy patch test (APT) in the diagnosis of food allergy in children with atopic dermatitis
    Soloni Afra Pires Levy, Sergio Duarte Dortas Junior, Andrea Huguenim Silva Pires, Augusto Tiaqui Abe, Solange Oliveira Rodrigues Valle, Vilma Perez Coelho, Ludwig Ruppert Hahnstadt, Alfeu Tavares França
    Anais Brasileiros De Dermatologia, 2012
  • Cross-cultural adaptation of the Brazilian-Portuguese version of the chronic urticaria quality-of-life questionnaire - CU-Q 2oL
    G. A. C. Dias, G. V. Pires, S. O. R. Valle, A. T. França, J. A. Papi, S. D. Dortas, S. A. P. Levy, I. Baiardini, G. W. Canonica
    Allergy European Journal of Allergy and Clinical Immunology, 2011
  • Delayed pressure urticaria with systemic manifestations - Case report
    Sérgio Duarte Dortas Jr, Solange Oliveira Rodrigues Valle, Andréa Huguenim Silva Pires, Patrícia Viana Guimarães, Adriana Smith Jorge
    Anais Brasileiros De Dermatologia, 2009